Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Correction for Food Recall Warning for Certain President's Choice brand Powdered Infant Formula


Product photos are available: http://inspection.gc.ca/about-the-cfia/newsroom/food-recall-warnings/complete-listing/2019-10-13/eng/1571011106989/1571011112859

OTTAWA, Oct. 13, 2019  /CNW/ - The food recall warning of certain powdered infant formula issued on October 6, 2019 is revised to correctly identify the formula that may be contaminated with Cronobacter spp. President's Choice brand Lower Iron milk based powdered infant formula had been incorrectly identified as having been associated with the testing results.

Accordingly, the following product is no longer subject to a food recall warning:

Product

 

Brand

Product

Size

UPC

Codes

President's Choice

Lower Iron milk based powdered infant formula

900 g

0 60383 69839 3

EXP 2021 AU 29

 

It has now been confirmed that the testing results indicate that certain President's Choice brand Sensitive to lactose milk-based powdered infant formula may be contaminated with Cronobacter spp. Loblaw Companies Limited is recalling the formula described below.

The following product has been sold nationally and should not be consumed.

Recalled product

 

Brand

Product

Size

UPC

Codes

President's Choice

Sensitive to lactose milk-based powdered infant formula

638 g

0 60383 12994 1

EXP 2020 NO 05

 

What you should do

If you think you or a family member became sick from consuming a recalled product, call your doctor.

Check to see if you have the recalled product in your home. Recalled products should be thrown out or returned to the store where they were purchased.

Food contaminated with Cronobacter may not look or smell spoiled but can still cause illness. Although Cronobacter is not commonly linked to human illness, in rare cases it can cause serious or fatal infections. Cronobacter can cause rare bloodstream and central nervous system infections and has been associated with severe intestinal infection (necrotizing enterocolitis) and blood poisoning (sepsis), especially in newborns.

Background

This recall was triggered by the CFIA's surveillance activities. The CFIA is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated Food Recall Warnings.

The CFIA is verifying that industry is removing the recalled product from the marketplace.

Illnesses

There have been no reported illnesses associated with the consumption of this product.

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 17:48
On Wednesday, April 17, the San Joaquin Valley Health Fund (SJVHF) launched "Equity on the Road" a multi-city series of community town halls to deepen local understanding of state issues and to advocate for more resources in the San Joaquin Valley....

at 17:44
The Honourable Mark Holland, Minister of Health, will host an event at the University of Waterloo to highlight the federal budget's investments to support students. The Minister will be joined by Bryan May, Parliamentary Secretary to the Minister of...

at 17:31
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness. Moreover,...

at 17:00
Avicanna Inc. ("Avicanna" or the "Company") a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private...

at 16:46
Darling Ingredients Inc. announced today that it will host a conference call on Thursday, April 25, 2024, at 9 a.m. Eastern Time (8 a.m. Central Time) to discuss first quarter 2024 financial results, which will be released earlier that day, and...

at 16:45
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic...



News published on and distributed by: